blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP3071198

EP3071198 - TREATMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA [Right-click to bookmark this link]
StatusThe application has been withdrawn
Status updated on  12.01.2018
Database last updated on 11.11.2024
Most recent event   Tooltip12.01.2018Withdrawal of applicationpublished on 14.02.2018  [2018/07]
Applicant(s)For all designated states
Cymabay Therapeutics, Inc.
7999 Gateway Blvd, Suite 130
Newark, CA 94560 / US
[2016/39]
Inventor(s)01 / MARTIN, Robert L.
7999 Gateway Blvd.
Suite 130
Newark, CA 94560 / US
02 / MCWHERTER, Charles A.
7999 Gateway Blvd.
Suite 130
Newark, CA 94560 / US
03 / O'MARA, Patrick J.
7999 Gateway Blvd.
Suite 130
Newark, CA 94560 / US
 [2016/39]
Representative(s)Wills, Andrew Jonathan, et al
Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE / GB
[2016/39]
Application number, filing date14809184.614.11.2014
[2016/39]
WO2014US65742
Priority number, dateUS201361906837P20.11.2013         Original published format: US 201361906837 P
US201461942438P20.02.2014         Original published format: US 201461942438 P
US201461942941P21.02.2014         Original published format: US 201461942941 P
US201461974816P03.04.2014         Original published format: US 201461974816 P
US201461974785P03.04.2014         Original published format: US 201461974785 P
US201461974725P03.04.2014         Original published format: US 201461974725 P
[2016/39]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015077154
Date:28.05.2015
Language:EN
[2015/21]
Type: A1 Application with search report 
No.:EP3071198
Date:28.09.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 28.05.2015 takes the place of the publication of the European patent application.
[2016/39]
Search report(s)International search report - published on:EP28.05.2015
ClassificationIPC:A61K31/192, A61K31/4468, A61K31/7088, A61P3/06, A61K39/395
[2016/39]
CPC:
A61K31/192 (EP,KR,US); A61K31/4468 (EP,KR,US); A61K31/7088 (KR);
A61K39/3955 (EP,KR,US); A61P3/06 (EP,KR); A61P3/10 (EP,KR);
A61P43/00 (EP,KR); A61P9/00 (EP); A61P9/10 (EP,KR);
C07K16/40 (EP,KR,US); C12N15/113 (KR,US); A61K2300/00 (KR);
C12N2310/11 (KR,US); C12N2320/31 (KR,US) (-)
C-Set:
A61K31/192, A61K2300/00 (EP,US);
A61K31/4468, A61K2300/00 (US,EP);
A61K31/7088, A61K2300/00 (US,EP);
A61K39/3955, A61K2300/00 (US,EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/39]
TitleGerman:BEHANDLUNG VON HOMOZYGOTER FAMILIÄRER HYPERCHOLESTERINÄMIE[2016/39]
English:TREATMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA[2016/39]
French:TRAITEMENT DE L'HYPERCHOLESTÉROLÉMIE FAMILIALE HOMOZYGOTE[2016/39]
Entry into regional phase07.06.2016National basic fee paid 
07.06.2016Designation fee(s) paid 
07.06.2016Examination fee paid 
Examination procedure07.06.2016Examination requested  [2016/39]
23.02.2017Amendment by applicant (claims and/or description)
08.01.2018Application withdrawn by applicant  [2018/07]
Fees paidRenewal fee
10.11.2016Renewal fee patent year 03
13.11.2017Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[XDYI]US2010152295  (KARPF DAVID [US], et al);
 [Y]WO2012154999  (AMGEN INC [US], et al);
by applicantUS5712279
 US5739135
 US5883109
 US6066653
 US7301050
 US7407943
 US7635718
 US7709682
 US2010152295
 US7932268
 US8106095
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.